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Objective: to verify the association between the prognostic scores and the quality of life of 
candidates for heart transplantation. Method: a descriptive cross-sectional study with a 
convenience sample of 32 outpatients applying to heart transplantation. The prognosis was 
rated by the Heart Failure Survival Score (HFSS) and the Seattle Heart Failure Model (SHFM); 
and the quality of life by the Minnesota Living With Heart Failure Questionnaire (MLHFQ) and the 
Kansas City Cardiomyopathy Questionnaire (KCCQ). The Pearson correlation test was applied. 
Results: the correlations found between general quality of life scores and prognostic scores 
were (HFSS/MLHFQ r = 0.21), (SHFM/MLHFQ r = 0.09), (HFSS/KCCQ r = -0.02), (SHFM/KCCQ 
r = -0.20). Conclusion: the weak correlation between the prognostic and quality of life scores 
suggests a lack of association between the measures, i.e., worse prognosis does not mean worse 
quality of life and the same statement is true in the opposite direction.
Descriptors: Heart Failure; Quality of Life; Heart Transplantation; Prognosis; Ambulatory Care; 
Adult.
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Introduction
The availability of solid organs for transplantation is 
a problem worldwide(1-4). There had been an expressive 
increase in the number of cardiac transplantations (CT) 
in the world until the mid-1990s. Since then, due to 
improvements in the clinical management of heart 
failure (HF) and the inherent limitation of donors, the 
number of CT remains stable: 4,000 to 5,000(5). In Brazil, 
in 2016, of the 631 patients entered in the CT queue, 
145 died before receiving a heart, with only 357 CT being 
performed, which reaches 1.7 transplants per million 
population(6). These facts reinforce the need for an accurate 
indication for CT, considering the risk stratification of the 
patients and the patient’s desire to transplant. 
In this context, studies have described the 
prognostic scores in HF as well-used and accurate 
measures to stratify risk(7-8) and when associated 
to the peak of oxygen consumption (VO2) can help 
the indication of transplantation, according to the 
suggestion of the International Society for Heart and 
Lung Transplantation - ISHLT(9), whereas the specific 
instruments of Quality of Life (QoL) have shown to be 
accurate in assessing QoL in patients with HF(10-11).
Besides, scholars(12-14) recommend that nursing 
progresses in research practices to evaluate outcomes 
such as QoL, prognosis and readmission in patients with 
advanced HF and transplant candidates, as well as after 
CT and clinical follow-up.
Therefore, as the improvement of QoL, in addition 
to increased survival, is one of the objectives to be 
achieved with the indication of the CT, and as HF has an 
impact on QoL, besides as a poor prognosis, this article 
aims to check the association between the prognostic 
scores and the QoL of candidates for CT.
Method
This is a cross-sectional study delineated by a non-
probabilistic or convenience sample, delimited initially 
by all the adult patients listed and being prepared for 
CT of the National Institute of Cardiology (INC) in Rio 
de Janeiro.
Data were collected from March to August 2016. 
Inclusion criteria were outpatient candidates for HT; 
being 18 years of age or over; having performed 
ergospirometry. Exclusion criteria were patients who 
have been admitted during data collection without the 
possibility of hospital discharge; diagnosis of psychiatric 
illness; incomplete medical records regarding the data 
necessary to classify prognostic scores.
During the study period, 47 patients were potentially 
eligible and of these 32 patients were selected, as 
described in Figure 1.
Potentially elegible for the survey
- 47 patients
1 st stage – Data collection 
in medical records
Excluded
- 07 patients due to lack of data 
in medical records
- 01 patient due to depression
Included
- 39 patients 
Respecting the inclusion 
criteria
2 nd stage – Application of 
questionnaires  (KCCQ* y MLHFQ†)
Selected 
- 32 patients
Respecting the inclusion criteria
Excluded 
- 03 admissions without possibility of 
hospital discharge 
- 04 refuses to participate
*KCCQ - Kansas City Cardiomyopathy Questionnaire; †MLHFQ - Minnesota Living With Heart Failure Questionnaire.
Figure 1- Scheme for the selection of research subjects
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who were candidates for CT and to collect information 
on patients’ sociodemographic and clinical profile, as 
well as data for the classification by the Heart Failure 
Survival Score (HFSS) and the Seattle Heart Failure 
Model (SHFM), described in Figure 2.
Data collection was performed in the outpatient 
clinic of the INC, in two stages.
The first stage involved the data collection in 
medical records. The schedule of the certified physician 
for CT was used as a guide to identify the patients 
Epidemiological Profile Demographic Profile HFSS* SHFM†
Etiology of HF‡;
FEVE**;
CF§§ (NYHA||||);
Comorbidities;
Previous ICD***;
Previous PM;
Previous MRVS§§§;
Previous AMI¶|¶|¶|;
Previous Stroke.
Age;
Sex;
Schooling;
Occupation.
PM§/QRS|| >120ms¶| per LBBB†† or RBBB‡‡;
HR¶|¶| at rest;
Ischemic Etiology;
LVEF;
VO2††† peak;
ABP||||||;
Serum sodium.
Age;
Sex;
Ischemic Etiology;
LVEF;
FC (NYHA);
SBP‡‡‡;
Medicines:
Beta Blocker;
ACEI‡‡‡‡;
Spironolactone;
Statin;
ARB§§§§;
Allopurinol;
Diuretics: Type and Dose
Laboratory:
Serum sodium;
Total cholesterol;
Uric acid;
Hemoglobin;
Lymphocytes.
*HFSS - Heart Failure Survival Score; †SHFM - Seattle Heart Failure Model; ‡HF – Heart Failure; §PM – Pacemaker; ||QRS – Ventricular depolarization; 
¶ms – milliseconds; **LVEF – Left-Ventricular Ejection Fraction; ††LBBB – Left Bundle-Branch Block; ‡‡RBBB - Right Bundle-Branch Block; §§FC - Functional 
class; |||||NYHA - New York Heart Association; ¶¶HR – Heart Rate; ***ICD - Implantable Cardioverter-Defibrillator; †††VO2 - O2 consumption; 
‡‡‡SBP - Systolic blood pressure;; §§§MRVS - Myocardial Revascularization Surgery; ||||||ABP - Average Blood Pressure; ¶¶¶AMI - Acute Myocardial 
Infarction; ‡‡‡‡ACEI – Angiotensin-Conversting Enzyme Inhibitor; §§§§ARB – Angiotensin-Receptor Blocker.
Figure 2 - Variables collected in medical records 
For the second phase of this research, a pilot 
test was carried out with the application of three 
questionnaires from the Minnesota Living Heart 
Failure Questionnaire (MLHFQ) and the Kansas City 
Cardiomyopathy Questionnaire (KCCQ), and we found 
that patients were unable to answer them alone, 
which can be explained by the schooling that ranged 
from elementary to higher education in this sample. 
For this reason, the interview method was chosen for 
this phase, and therefore, it was performed after the 
medical consultation. The four patients who missed the 
consultations were contacted via telephone for a new 
appointment, of whom two refused to participate and two 
answered the questionnaires at the next appointment.
The research instruments used were SHFM, 
HFSS, KCCQ and MLHFQ. The SHFM consists of 20 
variables divided into clinical (age, sex, New York 
Heart Association - NYHA Functional Class - FC, weight, 
Left-Ventricular Ejection Fraction - LVEF, systolic 
blood pressure), medications (angiotensin-converting 
enzyme inhibitor - ACEI, beta-blocker-BB, angiotensin-
receptor blocker - ARB, statin, allopurinol, aldosterone 
antagonist and type-specific diuretics), laboratory data 
(hemoglobin, lymphocytes, uric acid, total cholesterol, 
serum sodium) and Resynchronization Therapy (CRT) or 
Implantable Cardioverter-Defibrillator (ICD)(15).
The HFSS is composed of six variables calculated 
by the following formula(16):
HFSS = [(0.0216 x resting heart rate) + (-0.0255 x 
mean systemic arterial pressure) + (-0.0464 x 
left-ventricular ejection fraction) + (-0.0470 x 
serum sodium) + (-0.0546 x oxygen consumption 
during maximal exercise) + (0.6083 x presence 
of intraventricular conduction defect) + (0.6931 x 
presence of coronary disease)]
The MLHFQ(17) is composed of 21 questions divided 
by two dimensions (physical and emotional) and total 
score. The total score is calculated with the sum of the 
questions ranging from 0 to 105, in which the higher the 
score, the worse the QoL.
And the KCCQ(18) is composed of 15 questions, 
with 23 items, organized in five dimensions: Physical 
limitation; Symptoms (frequency/severity/stability); 
Quality of life, Self-care; and Social limitation. The result 
of the score ranges from 0 to 100, in which the higher 
the score, the better the QoL.
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The collected data were compiled and processed 
by the Microsoft Excel® software of the Microsoft 
Office® package and the Statistical Package for Social 
Sciences (SPSS) 24 software, divided in three steps. 
The Shapiro-Wilk test was used to assess whether the 
sample distribution was normal.
In the first stage, simple descriptive statistics 
was performed to present the sociodemographic and 
clinical profile of the sample. The second step also 
consisted of a descriptive analysis of the prognostic 
scores (HFSS and SHFM) and the QoL scores (MLHFQ 
and KCCQ). 
The third step consisted of correlation analyzes 
between the two prognostic scores, with the QoL 
scores. The Pearson correlation coefficient (r) was 
used which presupposes a linear correlation between 
quantitative variables. For this study, we used the 
reference that categorizes the correlation at r = 0.10 
to 0.30 (weak); r = 0.40 to 0.6 (moderate); r = 0.70 
to 1 (strong).
The present study was approved by the 
Ethics and Research Committee of the hospital 
where the research was carried out under approval 
number 51348515.0.0000.5272, and all the participants 
signed the Informed Consent Form. 
Results
Table 1 presents the sociodemographic and clinical 
characteristics of the participants.
When classified by the HFSS, 89.2% of the patients 
were described as medium and low risk for mortality in 
one year ahead, however, when classified by the SHFM, 
90.6% were described as medium and high risk for 
mortality in one year ahead.
The mean QoL scores of the participants by the 
MLHFQ and KCCQ questionnaires are described in 
Table 2.
The Pearson correlation matrix between the general 
scores of quality of life instruments and the prognostic 
tools showed the following absolute values: HFSS x 
MLHFQ - 0.21; HFSS x KCCQ = 0.02; SHFM x MLHFQ = 
0.09; and SHFM x KCCQ - 0.20.
When analyzing the relationships between 
individual prognostic scores (HFSS and SHFM) with 
distinct quality of life scores (MLHFQ and KCCQ), we 
found in all cases a weak correlation, with the highest 
value found for r = 0.21, which suggests that there is 
no association between the two prognostic scores with 
the two QoL measurement instruments, that is, patients 
with worse prognosis may present good quality of life 
and vice versa. 
Table 1 - Sociodemographic and clinical characteristics 
of the sample (n = 32). Rio de Janeiro/RJ, Brazil, 2017
Patients’ Characteristics n = 32 %
Sex   
Female 14 43.75%
Male 18 56.25%
Age group (years)   
25-45 10 31.25%
46-55 10 31.25%
56-65 12 37.50%
Occupation   
Retired due to disability 18 56.24%
Sick leave by social security 7 21.88%
Others 7 21.88%
Schooling   
Elementary School (1st to 5th year) 8 25.00%
Secondary School (6th to 9th 
grade) 6 18.75%
High school 11 34.37%
Higher education 7 21.88%
Etiology   
Idiopathic 11 34.38%
Others 8 25.00%
Ischemic 7 21.88%
Valvar 4 12.50%
Chagasic 2 6.25%
Clinical Data   
SAH* 12 37.50%
Type II DM† 5 15.63%
AF‡ 9 28.13%
DLP§ 6 18.75%
FC|| NYHA¶ III 26 81.25%
FC NYHA IV 6 18.75%
ICD** 9 28.13%
PM†† 3 9.38%
Previous AMI‡‡ 9 28.13%
Previous stroke§§ 8 25.00%
Previous VS|||| 5 15.63%
Previous MRVS¶¶ 3 9.38%
*SAH - Systemic Arterial Hypertension; †DM - Diabetes Mellitus; ‡AF - Atrial 
fibrillation; §DLP - Dyslipidemia; ||FC - Functional Class; ¶NYHA - New York 
Heart Association; **ICD - Implantable Cardioverter-Defibrillator; ††PM - 
Pacemaker, ‡‡AMI - Acute Myocardial Infarction; ||||VS - Valvar Surgery; 
¶¶MRVS - Myocardial Revascularization Surgery.
Table 2 - Classification of the quality of life of participants 
by the Kansas City Cardiomyopathy Questionnaire and the 
Minnesota Living With Heart Failure Questionnaire, divided 
by dimensions (n = 32). Rio de Janeiro/RJ, Brazil, 2017.
Quality of Life 
Instruments Mean
Confidence 
interval 
Standard 
deviation
KCCQ* 
Symptom Frequency 64.00 ± 9.37 ± 27.04
Symptom Severity 65.36 ± 8.27 ± 23.86
Symptom Total Score 64.68 ± 8.36 ± 24.14
Quality of life  44.01 ± 7.56 ± 21.82
Social Limitation 43.42 ± 8.76 ± 25.30
Clinical Score 53.13 ± 7.92 ± 22.85
Overall Score 48.43 ± 6.90 ± 19.92
MLHFQ†
Overall Score 48.41 ± 8.32 ± 24.00
Physical Dimension 20.97 ± 4.01 ± 11.57
Emotional Dimension 10.56 ± 1.99 ± 5.75
*KCCQ - Kansas City Cardiomyopathy Questionnaire; †MLHFQ - Minnesota 
Living With Heart Failure Questionnaire.
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Discussion
The weak correlation between the prognostic 
scores and the QoL scores found in this study suggests 
that the patient’s perception, measured by QoL, as well 
as the prognostic score are a complementary measure 
to be used in clinical practice to aid the indication of CT.
No studies were found in the literature that associate 
prognostic scores with specific QoL instruments in HF, 
however one study evaluated the relationship between 
SHFM and a generic QOL instrument(19). Also, some 
studies have discussed the impact on the mortality of 
the specific instruments that measure QOL in HF(20-22).
One study longitudinally evaluated the relationship 
between SHFM and the health status valuation measured 
by the generic instrument EuroQol 5D (EQ-5D). Through 
a linear regression, they evaluated 2,331 patients with a 
2.5-year follow-up, with FC (NYHA) II to IV, LVEF ≤ 35%, 
showing that the increase of 1 unit in SHFM decreased by 
0.03 points the EQ-5D in the baseline assessment and 
that each year that the SHFM increased in one point, the 
EQ-5D decreased 0.006 points. These results showed 
that patients with high mortality risk had significantly 
lower EQ-5D and had higher rates of decline over time(19).
Regarding the impact on mortality, one study 
followed 8,443 patients with reduced LVEF for 
4.8 months and annually to assess the association 
of KCCQ with mortality in a randomized clinical trial 
comparing the use of enalapril with a new class of drugs, 
namely the LCZ696, which is a medicine composed of 
two complementary pharmacological agents. One of 
them, valsartan is a direct blocker of ARB, and the other 
is an inhibitor of neprilysin, an enzyme responsible for 
the degradation of endogenous vasodilator peptides, 
such as bradykinin, natriuretic peptides and calcitonin 
gene-related peptide, among others. And it concluded 
that KCCQ is associated with survival. Changes in QoL 
were better in patients treated with LCZ696 compared 
to enalapril, with consistency in most domains. These 
findings suggest that LCZ696 leads to better QoL(20).
Another study observed patients for three years, 
measuring B-type natriuretic peptide (BNP), and used 
the overall well-being evaluated by Cantril’s Ladder of 
Life, the MLHFQ to evaluate QoL and the Medical Outcome 
Study 36-item General Health Survey (RAND36) as 
a generic instrument and concluded that QoL is an 
independent predictor for survival(21).
In addition, a systematic review and a meta-analysis 
of prospective cohorts with patients with stabilized HF and 
with follow-up of at least 1 month, published between 2002 
and 2013, used KCCQ and MLHFQ to assess mortality and 
concluded that these instruments are significant mortality 
predictors besides the traditional risk factors(22).
Whereas ISHLT(9) suggests the use of the HFSS or 
SHFM prognostic scores associated with VO2 peak to aid 
the indication to the CT, the difference in the risks found 
between the two scores in the same sample can be 
explained by the different variables considered by each 
score, such as the VO2 peak present in the HFSS, an 
important predictor for the indication of CT and absent 
in SHFM, as well as drugs such as BB, spironolactone 
and ICD, which improve the survival of this population, 
present in SHFM, but absent in the HFSS. Thus, SHFM 
was more reliable for classification of the prognosis in 
this sample.
Regarding the evaluation of QoL, the mean scores of 
the MLHFQ are in line with the study that dealt with QoL in 
patients with advanced HF in the CT queue that resulted 
in a mean of the total score of 40.61, of the physical 
dimension of 14.96 and of the emotional dimension of 
7.70 (23). In the KCCQ, patients’ perception of QoL is 
similar to the study that evaluated the QoL of outpatients 
with FC III (NYHA): overall score (52.00), symptom total 
score (67.38), and symptom frequency score (67.00)(24).
Although it is assumed that the advanced stage 
disease presents more symptoms, causes greater 
dysfunction and consequently is related to poorer 
quality of life and worse prognosis(25-26), this may be true 
for an individual, but not necessarily it is the reality in a 
heterogeneous group of patients. 
Thus, even if a relationship between prognosis and 
quality of life can be established in larger samples, as has 
been the efforts of studies in this area, great individual 
variation should not be overlooked, since patients 
with the disease in similar stages may differentiate 
their symptoms and their limitations. In addition, non-
prognostic QoL measurements can provide relevant 
information on opportunities to improve patient care(27), 
especially in the case of indication for CT, which aims to 
improve survival and QoL(9,26).
This research had some limitations, such as the 
size of the sample, data collection in a single center, the 
absence of information in the records for collection, as 
well as a scarce literature regarding the association of 
the specific instruments of quality of life with the scores 
of HF prognostics. 
We suggest verifying the correlation between 
the prognostic scores and the physical and emotional 
dimensions of the QoL questionnaires (MLHFQ and KCCQ). 
Another approach would be to verify causality between 
instruments. In addition to these issues, an important 
study would be on the applicability of these tools in clinical 
practice, such as the feasibility of implementation in the 
workflow, integration with the institution’s electronic 
records and studies on costs, allowing the infrastructure 
to collect data and analyze them.
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Conclusion
The weak correlation between the prognostic and 
QoL scores suggests the non-association between the 
scores, i.e., worse prognosis does not mean worse QoL 
and the opposite is also true. 
The evaluation of the association between the HFSS 
and SHFM prognostic scores with specific instruments of 
QoL (MLHFQ and KCCQ) in candidates for CT is important 
and necessary, and the present study contributed to the 
pioneering nature of this practice in Brazil and also made 
it when using the KCCQ in the Brazilian population.
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